ARTICLE | Deals
BMS acquires Karuna, brightening the spotlight on schizophrenia, muscarinic receptors and neurology
By Lauren Martz, Executive Director, Biopharma Intelligence
December 23, 2023 1:10 AM UTC
![](https://platohealth.ai/wp-content/uploads/2023/12/persistence-creative-combinations-behind-karunas-14b-exit.gif)
![](https://platohealth.ai/wp-content/uploads/2023/12/persistence-creative-combinations-behind-karunas-14b-exit.png)
Bristol Myers Squibb is making a major move into neuroscience through the $14 billion acquisition of Karuna Therapeutics — a deal that also solidifies neuropsychology’s position as a major interest area for big pharma, and proves that persistence in challenging but promising biology can pay off.
Bristol Myers Squibb Co. (NYSE:BMY) will acquire the biotech for $330 per share, a 53% premium over the biotech’s close on Thursday and a 35% premium over its 52-week-high. It’s the second large neurology acquisition this month following the proposed buyout of Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) and its next-generation schizophrenia asset by AbbVie Inc. (NASDAQ:ABBV) for $8.7 billion…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651015/persistence-creative-combinations-behind-karuna-s-14b-exit